Other studies regarding the association of genetic variants and the prostate-specific antigen recurrence disclosed that common SNPs that were corelated with tumor aggressiveness and disease progression can also be used to predict BCR in PC patients receiving RP52–54. The gene discussed is BCR; the disease is pachyonychia congenita.